Relmada Therapeutics Inc (NASDAQ:RLMD) is making significant progress with its drug candidate NDV-01, targeting non-muscle invasive bladder cancer (NMIBC).Mizuho Securities sets a price target of $10 for RLMD, indicating a potential upside of approximately 69.2%.Positive mid-stage study results of NDV-01 show a 12-month complete response rate of 76%, driving a 42% surge in RLMD's stock.Relmada Therapeutics Inc (NASDAQ:RLMD) is a biopharmaceutical company focused on developing innovative therapies for centra ...